CAS No.
[625115-55-1(Unlabeled)]
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
methyl(4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl-13C-d3)carbamate
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
Riociguat-13C,d3 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Riociguat-13C,d3 usage and description
Riociguat 13CD3 is a medication that is primarily used to treat pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It is also used to treat other conditions such as Raynaud's phenomenon, a disorder that affects blood flow to the fingers and toes.
The chemical name of Riociguat 13CD3 is Methyl 4,6-diamino-2-(1-methoxy-1-methylethyl)-5-{[4-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-yl]amino}pyrimidine-7-carboxylate, and its molecular formula is C20H19N7O3. Riociguat 13CD3 belongs to a class of drugs called soluble guanylate cyclase (sGC) stimulators. It works by increasing the production of cyclic guanosine monophosphate (cGMP), which promotes the relaxation of blood vessels and improves blood flow.
Riociguat 13CD3 is available in the form of tablets for oral administration. The recommended dosage and duration of treatment may vary depending on the condition being treated, the patient's age, and overall health. Riociguat 13CD3 should be taken as directed by a healthcare provider and should not be stopped or changed without medical advice.
Like all medications, Riociguat 13CD3 may cause side effects such as headache, dizziness, nausea, and diarrhea. Rare but serious side effects may include bleeding, low blood pressure, and liver damage. It is important to inform a healthcare provider of any unusual symptoms or changes in health while taking Riociguat 13CD3.
